These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 11005643)
1. Possibilities for clinical use of prostacyclin in vascular disease. Poredos P Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643 [TBL] [Abstract][Full Text] [Related]
2. Possibilities for clinical use of prostacyclin in vascular disease. Poredoš P Pflugers Arch; 2000 Jan; 440(Suppl 1):R137-R138. PubMed ID: 28008512 [TBL] [Abstract][Full Text] [Related]
3. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148 [TBL] [Abstract][Full Text] [Related]
5. [The role of iloprost in the treatment of critical ischemia of the limbs]. Poggesi L; Comeglio M Ann Ital Med Int; 1993 Oct; 8 Suppl():71S-77S. PubMed ID: 7509614 [TBL] [Abstract][Full Text] [Related]
6. Iloprost: new indication. Not adequately assessed. Prescrire Int; 1999 Apr; 8(40):49-50. PubMed ID: 10848061 [TBL] [Abstract][Full Text] [Related]
7. Prostaglandin therapy in severe limb ischemia. Pardy BJ; Eastcott HH World J Surg; 1983 May; 7(3):353-62. PubMed ID: 6349140 [No Abstract] [Full Text] [Related]
8. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609 [TBL] [Abstract][Full Text] [Related]
9. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon. Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979 [TBL] [Abstract][Full Text] [Related]
10. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Grant SM; Goa KL Drugs; 1992 Jun; 43(6):889-924. PubMed ID: 1379160 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic use of prostacyclin in cardiovascular pathology]. Martelli M; Nicolosi G Minerva Med; 1983 Nov; 74(44):2665-70. PubMed ID: 6419178 [TBL] [Abstract][Full Text] [Related]
12. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Fink AN; Frishman WH; Azizad M; Agarwal Y Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602 [TBL] [Abstract][Full Text] [Related]
13. [Ischemia of the limbs. Angiodyn, Toulouse, October 1988]. Vitoux JF Rev Prat; 1989 Mar; 39(7):587-8. PubMed ID: 2468177 [No Abstract] [Full Text] [Related]
14. Is it possible to improve outcome in patients undergoing surgery for acute limb ischemia? Can iloprost, a prostacyclin analogue, be helpful? de Donato G; Gussoni G; de Donato G Chir Ital; 2004; 56(6):769-80. PubMed ID: 15771029 [TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease. Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Bozkurt AK; Köksal C; Demirbas MY; Erdoğan A; Rahman A; Demirkiliç U; Ustünsoy H; Metin G; Yillik L; Onol H; Cinar B; Karaçelik M; Erdinç I; Bolcal C; Sayin AG; Int Angiol; 2006 Jun; 25(2):162-8. PubMed ID: 16763533 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of severe Raynaud syndrome in scleroderma or thromboangiitis obliterans with prostacyclin (prostaglandin I2)]. Rüthlein HJ; Riegger G; Auer IO Z Rheumatol; 1991; 50(1):16-20. PubMed ID: 2058317 [TBL] [Abstract][Full Text] [Related]
19. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290 [TBL] [Abstract][Full Text] [Related]